Regeneron (REGN) Halted Ahead of FDA Panel Review of Praluent

(Updated - June 9, 2015 7:05 AM EDT)

Regeneron (NASDAQ: REGN) trading halted with news pending.

UPDATE - The halt comes ahead of the U.S. FDA's Endocrinologic and Metabolic Drugs Advisory Committee, which will review Regeneron and Sanofi's PCSK9 (proprotein convertase subtilisin/kexin type 9) antibody, Praluent.

BMO Capital recently commented on the matter here, and RBC Capital commented here.

You May Also Be Interested In

• BMO Capital Upgrades Casey's General Stores (CASY) to Outperform, 'Opportunity Knocks'
• BMO Capital on Meta Platforms Inc. (META): 'incrementally positive on the shift towards an ROI-generating business'
• RBC Capital Downgrades Bucher Industries AG (BUCN:SW) (BCHHF) to Sector Perform